ND-026

J&J Acquires Atopic Dermatitis Drug NM26 in $1.25 Billion Deal with Numab Therapeutics

4 months ago

Johnson & Johnson has entered into a $1.25 billion agreement to acquire NM26, a bispecific antibody for atopic dermatitis (AD) from Numab Therapeutics. NM26 targets IL-4 receptors and IL-31, offering potential first-in-class therapy benefits for AD patients. The deal underscores J&J's commitment to developing innovative treatments for inflammatory diseases.

Johnson & Johnson to Acquire Yellow Jersey Therapeutics for $1.25 Billion, Bolstering Atopic Dermatitis Pipeline

a year ago

• Johnson & Johnson will acquire Yellow Jersey Therapeutics for $1.25 billion, gaining rights to NM26, a Phase 2-ready bispecific antibody for atopic dermatitis. • NM26 targets both IL-4Rα and IL-31, addressing inflammation and itch, potentially offering advantages over existing treatments like Dupixent. • The acquisition aligns with J&J's strategy to expand its immunology portfolio with differentiated bispecifics, following recent deals in oncology and immunology. • Numab Therapeutics' MATCH™ technology platform, used to develop NM26, is validated by this deal, highlighting its potential for creating novel multi-specific antibodies.

J&J Acquires Atopic Dermatitis Drug NM26 in $1.25 Billion Deal with Numab Therapeutics

Johnson & Johnson to Acquire Yellow Jersey Therapeutics for $1.25 Billion, Bolstering Atopic Dermatitis Pipeline

Drug Development Updates